Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1146/annurev-med-042220-011857 http://scihub22266oqcxt.onion/10.1146/annurev-med-042220-011857 34379444!ä!34379444 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34379444&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Annu+Rev+Med 2022 ; 73 (ä): 129-147 Nephropedia Template TP {{tp|p=34379444|t=2022. COVID-19 and Diabetes |pdf=|usr=}}{{34379444}} gab.com Text COVID-19 and Diabetes JO: Annu Rev Med http://www.kidney.de/pget.php?&tw=1&pmid=34379444 #FOAvip The prevalence of diabetes in people with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has varied worldwide. Most of the available evidence suggests a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcome, no conclusive evidence yet suggests direct tropism of SARS-CoV-2 on the beta cells of pancreatic islets. While all approved oral antidiabetic agents appear to be safe in people with T2DM having COVID-19, no conclusive data are yet available to indicate a mortality benefit with any class of these drugs, in the absence of large randomized controlled trials. Twit Text FOAVip COVID-19 and Diabetes ????Annu Rev Med http://www.kidney.de/pget.php?&tw=1&pmid=34379444 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34379444 #FOAvip English Wikipedia <ref>{{Cite pmid|34379444}}</ref> COVID-19 and Diabetes #MMPMID34379444 Singh AK; Khunti K Annu Rev Med 2022[Jan]; 73 (ä): 129-147 PMID34379444show ga The prevalence of diabetes in people with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has varied worldwide. Most of the available evidence suggests a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcome, no conclusive evidence yet suggests direct tropism of SARS-CoV-2 on the beta cells of pancreatic islets. While all approved oral antidiabetic agents appear to be safe in people with T2DM having COVID-19, no conclusive data are yet available to indicate a mortality benefit with any class of these drugs, in the absence of large randomized controlled trials. |*COVID-19[MESH] |*Diabetes Mellitus, Type 2/drug therapy/epidemiology[MESH] |*Hyperglycemia[MESH] |Humans[MESH] |Hypoglycemic Agents/therapeutic use[MESH]COVID-19 and Diabetes (epmc).pdf DeepDyve Pubget Overpricing